KalVista Pharmaceuticals Inc (KALV)’s valuation ratios: A closer look

The closing price of KalVista Pharmaceuticals Inc (NASDAQ: KALV) was $11.40 for the day, down -3.88% from the previous closing price of $11.86. In other words, the price has decreased by -$0.46 from its previous closing price. On the day, 817261 shares were traded. KALV stock price reached its highest trading level at $11.79 during the session, while it also had its lowest trading level at $11.03.

Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.

Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!

Get the FREE Report with all the details here.


Sponsored

Ratios:

Our analysis of KALV’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 5.44 and its Current Ratio is at 5.44. In the meantime, Its Debt-to-Equity ratio is 0.08 whereas as Long-Term Debt/Eq ratio is at 0.07.

Upgrades & Downgrades

In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, H.C. Wainwright on June 15, 2020, initiated with a Buy rating and assigned the stock a target price of $30.

On July 29, 2019, SVB Leerink started tracking the stock assigning a Outperform rating and target price of $31.

On March 20, 2019, Needham started tracking the stock assigning a Buy rating and target price of $35.Needham initiated its Buy rating on March 20, 2019, with a $35 target price.

Insider Transactions:

Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Feb 20 ’24 when Feener Edward P. sold 28,288 shares for $14.07 per share. The transaction valued at 397,929 led to the insider holds 62,157 shares of the business.

Crockett Thomas Andrew sold 24,888 shares of KALV for $351,289 on Feb 20 ’24. The CEO now owns 211,203 shares after completing the transaction at $14.11 per share. On Feb 20 ’24, another insider, Palleiko Benjamin L, who serves as the CFO, CBO of the company, sold 22,802 shares for $14.11 each. As a result, the insider received 321,846 and left with 187,315 shares of the company.

Valuation Measures:

Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, KALV now has a Market Capitalization of 481.37M and an Enterprise Value of 413.23M. Its current Enterprise Value per Revenue stands at 76.33 whereas that against EBITDA is -3.36.

Stock Price History:

Over the past 52 weeks, KALV has reached a high of $16.88, while it has fallen to a 52-week low of $6.83. The 50-Day Moving Average of the stock is 13.51, while the 200-Day Moving Average is calculated to be 10.76.

Shares Statistics:

KALV traded an average of 806.06K shares per day over the past three months and 625.88k shares per day over the past ten days. A total of 34.17M shares are outstanding, with a floating share count of 27.55M. Insiders hold about 34.70% of the company’s shares, while institutions hold 60.41% stake in the company. Shares short for KALV as of Mar 15, 2024 were 4.92M with a Short Ratio of 6.10, compared to 2.99M on Feb 15, 2024. Therefore, it implies a Short% of Shares Outstanding of 11.66% and a Short% of Float of 12.30%.

Earnings Estimates

The firm’s stock currently is rated by 5 analysts. On average, analysts expect EPS of -$0.71 for the current quarter, with a high estimate of -$0.55 and a low estimate of -$0.79, while EPS last year was -$0.77. The consensus estimate for the next quarter is -$0.65, with high estimates of -$0.57 and low estimates of -$0.73.

Analysts are recommending an EPS of between -$2.84 and -$3.16 for the fiscal current year, implying an average EPS of -$3.03. EPS for the following year is -$2.44, with 5 analysts recommending between -$1.71 and -$3.11.

Most Popular